Cemiplimab in Locally Advanced or Metastatic Secondary Angiosarcomas (CEMangio): A Phase II Clinical Trial and Biomarker Analyses.

Saved in:
Bibliographic Details
Title: Cemiplimab in Locally Advanced or Metastatic Secondary Angiosarcomas (CEMangio): A Phase II Clinical Trial and Biomarker Analyses.
Authors: van Ravensteijn SG; Department of Medical Oncology, Radboud University Medical Center, Nijmegen, the Netherlands., de Haan JJ; Department of Medical Oncology, University Medical Center Groningen, Groningen, the Netherlands., Gelderblom H; Department of Medical Oncology, Leiden University Medical Center, Leiden, the Netherlands., Nederkoorn MJL; Department of Medical Oncology, Radboud University Medical Center, Nijmegen, the Netherlands., Hillebrandt-Roeffen MHS; Department of Medical Oncology, Radboud University Medical Center, Nijmegen, the Netherlands., Gorris MAJ; Department of Medical BioSciences, Radboud University Medical Center, Nijmegen, the Netherlands., de Bitter TJJ; Department of Human Genetics, Radboud University Medical Center, Nijmegen, the Netherlands., Boleij A; Department of Pathology, Radboud University Medical Center, Nijmegen, the Netherlands., Gusinac A; Department of Pathology, Radboud University Medical Center, Nijmegen, the Netherlands., Ederveen THA; Department of Medical BioSciences, Radboud University Medical Center, Nijmegen, the Netherlands., Flucke UE; Department of Pathology, Radboud University Medical Center, Nijmegen, the Netherlands., Bonenkamp JJ; Department of Surgery, Radboud University Medical Center, Nijmegen, the Netherlands., Speetjens FM; Department of Medical Oncology, Leiden University Medical Center, Leiden, the Netherlands., Kaal SEJ; Department of Medical Oncology, Radboud University Medical Center, Nijmegen, the Netherlands., Smits M; Department of Medical Oncology, Radboud University Medical Center, Nijmegen, the Netherlands., Bol KF; Department of Medical Oncology, Radboud University Medical Center, Nijmegen, the Netherlands.; Department of Medical BioSciences, Radboud University Medical Center, Nijmegen, the Netherlands., van Herpen CML; Department of Medical Oncology, Radboud University Medical Center, Nijmegen, the Netherlands., Versleijen-Jonkers YMH; Department of Medical Oncology, Radboud University Medical Center, Nijmegen, the Netherlands., Desar IME; Department of Medical Oncology, Radboud University Medical Center, Nijmegen, the Netherlands.
Source: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2025 Sep 02; Vol. 31 (17), pp. 3678-3691.
Publication Type: Journal Article; Clinical Trial, Phase II; Multicenter Study
Journal Info: Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 9502500 Publication Model: Print Cited Medium: Internet ISSN: 1557-3265 (Electronic) Linking ISSN: 10780432 NLM ISO Abbreviation: Clin Cancer Res Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1557-3265
DOI:10.1158/1078-0432.CCR-25-0311